AAO Journal Archive
- Classification of Vitreous Seeds in Retinoblastoma
- Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia
- Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
- Correlation of Histologic Features with In Vivo Imaging of Reticular Pseudodrusen
- Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials
- Pharmacotherapies for Retinal Detachment
- Can Automated Imaging for Optic Disc and Retinal Nerve Fiber Layer Analysis Aid Glaucoma Detection?
- Suture Colonization Rate in Adjustable Strabismus Surgery
- Genetic and Dietary Factors Influencing the Progression of Nuclear Cataract
- Diagnostic Accuracy of Optical Coherence Tomography and Scanning Laser Tomography for Identifying Glaucoma in Myopic Eyes
Find an Eye MD near you!
- Details
To determine whether vitrectomy surgery rates have changed over the past decade and factors affecting the odds of undergoing this procedure.
Read more: Rates of Vitrectomy among Enrollees in a United States Managed Care Network, 2001–2012
- Details
Subthreshold depression is highly prevalent in visually impaired older adults and an important risk factor for major depressive disorder.1 For early diagnosis and treatment, it is important to identify patients who are at high risk of having subthreshold depression. Former research found inconsistent results and prediction models were never validated externally.2 Therefore, the aim of this study was to assess comprehensively potential predictor variables by internally validating a prediction model for subthreshold depression in a European sample and validating this model externally in a comparable Australian sample.
Read more: Validated Prediction Model of Depression in Visually Impaired Older Adults
- Details
To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD).
- Details
Conjunctival myxoma is a rare benign tumor that accounts for <0.001% of conjunctival lesions.1 It is important to recognize this entity, because it might be associated with cardiac myxoma, which can be life threatening.2 Based on a series of 4 cases, Herwig et al2 recently described the new entity, the conjunctival stromal tumor (COST), with its name deduced from the well-known gastrointestinal stromal tumor, showing a partially similar immunomarker profile. Positive markers for COST include CD34, vimentin, and partially for CD68; negative markers include S100 and smooth muscle actin.
Read more: Conjunctival Stromal Tumor: Expansion of Findings in a Newly Described Entity
- Details
To describe the association between morphologic features on fundus photography (FP), fluorescein angiography (FA), and optical coherence tomography (OCT) and visual acuity (VA) in the second year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).